Advanced Analytical Solutions for Cell Therapies

Nordic Cell Therapy Analytics focuses on the development and application of advanced analytical tools to support the characterization, quality control, and development of cell-based therapies.Cell therapies require robust and meaningful analytical strategies to ensure identity, safety, potency, and consistency. We combine deep biological understanding with practical development experience to design assays and analytical frameworks adapted to the unique challenges of living medicines.Through analytical innovation and collaboration with partners across academia and industry, we aim to strengthen the scientific foundation supporting next-generation cell therapies.

Available Assays & Custom Analytical development

Beyond the assays currently offered, we work closely with partners to address specific analytical challenges that arise during the development of cell-based therapies.Each program presents unique biological and technical questions, and in many cases existing analytical approaches may need to be adapted or newly developed. Through collaborative engagement with our partners, we support the design and implementation of tailored analytical strategies and assays aligned with the specific needs of each project.

In-Process Control (IPC) Platform

Stage-specific biomarker strategies supporting process consistency, scalability, and GMP-oriented cell therapy manufacturing.

Our IPC platform focuses on the identification of biologically relevant markers that reflect cell state, differentiation progression, and manufacturing robustness throughout development and scale-up activities.

• Early deviation detection
• Improved process consistency
• Reduced manufacturing risk
• Tailored IPC frameworks for specific processes

Our approach combines advanced analytical methodologies with practical cell therapy development experience to support scalable and phase-appropriate manufacturing strategies.

Starting Material Genetic Assessment

Tubes - Starting material genetic assessment

Comprehensive genetic assessment of human pluripotent stem cell (hPSC) lines to support the selection of suitable starting material for cell therapy development.

Our assay package evaluates candidate cell lines prior to master cell bank (MCB) generation, focusing on genomic alterations and disease-associated variants that may impact safety, manufacturability, or long-term development potential.

• Early identification of genetic liabilities
• Support for informed starting material selection
• Reduced downstream development risk
• Stronger foundation for regulatory progression

Our approach combines advanced genomic analysis with practical cell therapy development expertise to provide phase-appropriate and actionable insights tailored to each program.
‍

We welcome discussions with partners interested in applying these assays to their specific programs. Each project presents unique scientific and technical challenges, and we work closely with our partners to define the most relevant analytical approach, scope, and level of support.

Whether applying existing assays or developing tailored solutions, we aim to provide practical and actionable insights aligned with your development needs.

Copenhagen, 2300, Denmark
Nordic Cell Therapy Group Aps, a Danish private limited company
(CVR-nummer 46007441)